Protocols - Hemorio

EXCLUSION CRITERIA (should not be included in treatment protocol):
PERMANENTS Hypersensibility to HU
PROVISORY:
Any one of the
following:
Leucocytes count < 2.500/mm 3 ;and/or neutrophil count < 1.500/mm 3 ;
Hemoglobin < 4,5 g/dl;
Reticulocyte < 70.000/mm 3 (when Hgb < 8 g/dl)
Pregnancy (there is evidence of animal teratogenicity, but not in human
beings)
SPECIAL SITUATIONS: due to possible drug adverse effects, the risk/benefit ratio must be carefully
evaluated in the following cases:
(a) BREASTFEEDING: It is known that HU is excreted in milk. Its use might be avoided during
breastfeeding or be discontinued the breastfeeding;
(b) URICOSURIA: HU use may increase serum levels of uric acid. Patients with baseline levels above
normal limits must be monitored every month.
(c) RENAL INSUFFICIENCY: evaluation together with nephrology.
(d) LIVER INSUFFICIENCY: There is no enough data to guide dose adjustment in this situation. Patients
(e) DRUG INTERACTION: The concomitant administration with other drugs that may produce medullar
depression must be close monitored.
37